NATCO launches Bosentan Tablets for oral suspension in US with 180-day exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
TFOS is indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated